Leerink Partnrs Forecasts Envista’s Q1 Earnings (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for Envista in a research note issued to investors on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $0.20 per share for the quarter, down from their previous estimate of $0.22. The consensus estimate for Envista’s current full-year earnings is $1.00 per share. Leerink Partnrs also issued estimates for Envista’s Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.22 EPS, Q4 2025 earnings at $0.24 EPS, FY2025 earnings at $0.84 EPS, FY2026 earnings at $1.08 EPS and FY2028 earnings at $1.46 EPS.

Several other analysts have also commented on NVST. Piper Sandler raised their price objective on shares of Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. lowered their target price on Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Morgan Stanley reduced their price target on Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Thursday, March 6th. Finally, UBS Group dropped their target price on shares of Envista from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Monday, March 10th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.18.

Envista Trading Down 0.5 %

Shares of NVST opened at $15.46 on Friday. Envista has a 1-year low of $14.22 and a 1-year high of $23.00. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. The firm’s 50-day moving average price is $18.41 and its 200-day moving average price is $19.35. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -2.38, a PEG ratio of 1.27 and a beta of 1.12.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%.

Institutional Trading of Envista

A number of institutional investors and hedge funds have recently bought and sold shares of NVST. Treasurer of the State of North Carolina lifted its stake in shares of Envista by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 75,560 shares of the company’s stock worth $1,458,000 after buying an additional 480 shares in the last quarter. Amalgamated Bank lifted its position in Envista by 0.7% in the 4th quarter. Amalgamated Bank now owns 80,380 shares of the company’s stock valued at $1,551,000 after acquiring an additional 523 shares in the last quarter. GAMMA Investing LLC boosted its stake in Envista by 30.5% during the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after purchasing an additional 538 shares during the last quarter. M&T Bank Corp boosted its stake in Envista by 4.2% during the 4th quarter. M&T Bank Corp now owns 16,621 shares of the company’s stock valued at $320,000 after purchasing an additional 676 shares during the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Envista by 2.5% in the 4th quarter. Assetmark Inc. now owns 39,624 shares of the company’s stock worth $764,000 after purchasing an additional 983 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.